MilliporeSigma
  • Home
  • Search Results
  • Cross-platform toxicogenomics for the prediction of non-genotoxic hepatocarcinogenesis in rat.

Cross-platform toxicogenomics for the prediction of non-genotoxic hepatocarcinogenesis in rat.

PloS one (2014-05-17)
Michael Römer, Johannes Eichner, Ute Metzger, Markus F Templin, Simon Plummer, Heidrun Ellinger-Ziegelbauer, Andreas Zell
ABSTRACT

In the area of omics profiling in toxicology, i.e. toxicogenomics, characteristic molecular profiles have previously been incorporated into prediction models for early assessment of a carcinogenic potential and mechanism-based classification of compounds. Traditionally, the biomarker signatures used for model construction were derived from individual high-throughput techniques, such as microarrays designed for monitoring global mRNA expression. In this study, we built predictive models by integrating omics data across complementary microarray platforms and introduced new concepts for modeling of pathway alterations and molecular interactions between multiple biological layers. We trained and evaluated diverse machine learning-based models, differing in the incorporated features and learning algorithms on a cross-omics dataset encompassing mRNA, miRNA, and protein expression profiles obtained from rat liver samples treated with a heterogeneous set of substances. Most of these compounds could be unambiguously classified as genotoxic carcinogens, non-genotoxic carcinogens, or non-hepatocarcinogens based on evidence from published studies. Since mixed characteristics were reported for the compounds Cyproterone acetate, Thioacetamide, and Wy-14643, we reclassified these compounds as either genotoxic or non-genotoxic carcinogens based on their molecular profiles. Evaluating our toxicogenomics models in a repeated external cross-validation procedure, we demonstrated that the prediction accuracy of our models could be increased by joining the biomarker signatures across multiple biological layers and by adding complex features derived from cross-platform integration of the omics data. Furthermore, we found that adding these features resulted in a better separation of the compound classes and a more confident reclassification of the three undefined compounds as non-genotoxic carcinogens.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
Sigma-Aldrich
Chlorazol Black
Sigma-Aldrich
trans-Dehydroandrosterone, ≥99%
Sigma-Aldrich
Acetamide, ≥99.0% (GC)
Supelco
Diethylstilbestrol, VETRANAL®, analytical standard
Sigma-Aldrich
Diethylstilbestrol, ≥99% (HPLC)
Sigma-Aldrich
Acetamide, sublimed, 99%
Diethylstilbestrol, European Pharmacopoeia (EP) Reference Standard
Supelco
Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Nifedipine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acetamide, ~99% (GC)
Supelco
Acetamide, analytical standard
USP
Nifedipine, United States Pharmacopeia (USP) Reference Standard
Cyproterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Thioacetamide, ACS reagent, ≥99.0%
Sigma-Aldrich
Thioacetamide, reagent grade, 98%
Supelco
Cefuroxime, VETRANAL®, analytical standard
Supelco
Piperonylbutoxide, PESTANAL®, analytical standard
Sigma-Aldrich
L-Ethionine, ≥99% (TLC)
Sigma-Aldrich
Cyproterone acetate, ≥98%
Sigma-Aldrich
Phenobarbital
Sigma-Aldrich
Diethylstilbestrol, mixture of cis and trans, 97%
Sigma-Aldrich
Piperonylbutoxide, technical grade, 90%
Cyproterone acetate, European Pharmacopoeia (EP) Reference Standard